- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05063110
Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB (HLH-JAK)
Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB a Phase II Prospective Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This project aims to test the effectiveness of ITACITINIB in sporadic Hemophagocytosis Lymphohistiocytosis (HLHs). The existence of an IFN-γ signature, in HLHs, is a strong rational for testing the use of a JAK1 inhibitor in the treatment of HLHs. We hypothesize that ITACITINIB, an inhibitor of JAK-1, may be a therapeutic of interest in the treatment of non-severe HLHs in replacement of corticosteroids by inhibiting the production and effects of IFN-γ but also those of other pro-inflammatory cytokines. The use JAK-1 inhibitor instead of corticosteroids in patients with HLHs without any sign of severity is justified by its probable lesser toxicity and higher efficiency.
In this proof of concept study, because of the vital risk associated with severe HLH and the efficacy of Etoposide in this setting, we will first include only patients with moderate HLHs
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Coralie BLOCH-QUEYRAT, MD
- Phone Number: 0148957732
- Email: coralie.bloch-queyrat@aphp.fr
Study Contact Backup
- Name: Zahia Ben Abdesselam, Project Manager
- Phone Number: 0148957435
- Email: zahia.ben-abdesselam@aphp.fr
Study Locations
-
-
-
Bobigny, France, 93000
- Recruiting
- Hopital Avicenne
-
Contact:
- BLOCH Coralie, Dr
- Email: coralie.bloch-queyrat@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients age > 18 years,
- Patient is willing to provide written informed consent prior to enrolment and agrees to follow the protocol
- Patient known to have systemic juvenile idiopathic arthritis are classified as having HLH
- Negative pregnancy test for woman of childbearing potential, woman of childbearing potential should have reliable contraception for the duration of the study
- Be either affiliated to, or a beneficiary of, a social security category
Exclusion Criteria:
- Organ failure: confusion, organic kidney failure KDIGO 2 criteria, liver failure (Factor V < 50%), heart failure, respiratory failure.
- Fibrinogen < 0.50 g/l, platelets <20G/L
- Indication to intensive care unit transfer on an organ failure requiring assistance (dialysis, Ventilation (assisted or VNI), shock regardless of the origin.
- Breastfeeding women
- Patient participating in another investigational therapeutic study
- Women with a positive pregnancy test or not willing to take contraceptive measures
- Known allergies, hypersensitivity, or intolerance to any of the ITACITINIB or excipients, or similar compounds
- Current or history of recurrent infections, including HBV, HCV
- Participants with active HBV or HCV infection that requires treatment or who are at risk for HBV reactivation (ie Positive HBs Ag serology)
- Candidates positive for HCV antibody and positive PCR RNA HCV
- HIV infection with positive viral charge
- Protected adults (including individual under guardianship by court order)
- Vulnerable adults, under a safeguard of justice measure
- Adults deprived of their liberty by judicial or administrative decision
- Persons under psychiatric care without their consent
- Persons admitted to social institution for purposes other this research
- Adults under legal protection (guardianship or curatorship)
- Persons unable to express their consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment arm
300 mg of ITACITINIB will be administrated per os every day for 30 days, dose with reduction to 200 mg per safety is allowed if AEs are observed or if co-administered a strong CYP3A inhibitor
|
Administration of 300 mg of ITACITINIB per os every day for 30 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of ITACITINIB
Time Frame: At day 15
|
Efficacy at day 15 of ITACITINIB treatment in non-severe adults HLH
|
At day 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate of ITACITINIB at D8 on clinical and biological symptoms of primitive/refractory/relapse adults HLHs without severity criteria
Time Frame: day 8
|
Response rate at D8 of treatment
|
day 8
|
Efficacy at the day of etiologic treatment if patients received at least 7 days of treatment (ITACITINIB taken until J15)
Time Frame: At day 15
|
Rate of complete response to ITACITINIB treatment for HLHs in adults without any sign of severity at the day of etiologic treatment if patients have been treated by ITACITINIB at least during seven days.
Response to ITACITINIB is evaluated at the day of etiologic treatment on the major and minor diagnostic criteria of HLH
|
At day 15
|
Toxicity of ITACITINIB
Time Frame: 21 months
|
Toxicity of ITACITINIB not related to evolution of HLH (cytopenia, worsening of hepatic balance, secondary infections)
|
21 months
|
Rescue therapy
Time Frame: 21 months
|
In the case of worsening, treatment will be stopped and switch for HLH specific treatment as VP16, (etoposide)
|
21 months
|
Reduction of plasma cytokines level between D0 and D15 and correlation to the therapeutic response to D15
Time Frame: At day 15
|
Range of decrease in plasma rate of IFN-Gamma, IP-10, Il-1, Il-6, IL-10, TNF-alpha, between D0 and D15 of ITACITINIB treatment in each patient group: response and progression
|
At day 15
|
Clinical, biological, associated diseases characteristics of patients having CR, PR, Progression
Time Frame: 21 months
|
Clinical, biological, associated diseases and evolutions characteristics of patients in each response
|
21 months
|
Overall survival at 3
Time Frame: 3 months
|
Overall survival at 3
|
3 months
|
Response rate of ITACITINIB at D30 on clinical and biological symptoms of primitive/refractory/relapse adults HLHs without severity criteria
Time Frame: day 30
|
Response rate at D30 of treatment
|
day 30
|
Response rate of ITACITINIB at D90 on clinical and biological symptoms of primitive/refractory/relapse adults HLHs without severity criteria
Time Frame: day 90
|
Response rate at D90 of treatment
|
day 90
|
Collaborators and Investigators
Collaborators
Publications and helpful links
General Publications
- Menasche G, Feldmann J, Fischer A, de Saint Basile G. Primary hemophagocytic syndromes point to a direct link between lymphocyte cytotoxicity and homeostasis. Immunol Rev. 2005 Feb;203:165-79. doi: 10.1111/j.0105-2896.2005.00224.x.
- Pachlopnik Schmid J, Ho CH, Chretien F, Lefebvre JM, Pivert G, Kosco-Vilbois M, Ferlin W, Geissmann F, Fischer A, de Saint Basile G. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med. 2009 May;1(2):112-24. doi: 10.1002/emmm.200900009.
- Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood. 2005 Feb 15;105(4):1648-51. doi: 10.1182/blood-2004-08-2997. Epub 2004 Oct 5.
- Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013 May 23;32(21):2601-13. doi: 10.1038/onc.2012.347. Epub 2012 Aug 6.
- Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood. 2016 Jul 7;128(1):60-71. doi: 10.1182/blood-2016-02-700013. Epub 2016 May 24.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- APHP 201454
- 2021-000407-20 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adults Patients Having Non Severe HLH
-
University of LiegeCompletedDisorders of Consciousness | Severe Brain Injury | Post-comatose Non-communicative PatientsBelgium
-
University of LiegeCompletedDisorders of Consciousness | Minimally Conscious State | Severe Brain Injury | Post-comatose Non-communicative Patients | Vegetative StateBelgium
-
University Hospital, GrenobleTerminatedPsychiatric Adults PatientsFrance
Clinical Trials on Itacitinib
-
Incyte CorporationCompletedRheumatoid ArthritisUnited States, Puerto Rico
-
Incyte CorporationActive, not recruitingB-cell MalignanciesUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingSystemic SclerosisFrance
-
Incyte CorporationTerminatedBronchiolitis Obliterans SyndromeUnited States, Belgium, Canada
-
Incyte CorporationCompletedPolycythemia Vera | Myelofibrosis | ThrombocythemiaSpain, United States, Germany, Austria, Belgium, Italy, Poland
-
Imperial College LondonIncyte Biosciences UK LtdActive, not recruitingAdvanced Hepatocellular CarcinomaUnited Kingdom
-
Incyte CorporationAvailableSTAT1 Gain-of-Function Disease
-
John LevineCompletedGVHD | Low Risk Acute Graft-versus-host Disease | Graft-versus-host-diseaseUnited States
-
Incyte CorporationCompletedMPN (Myeloproliferative Neoplasms)Canada, United States, Australia
-
Columbia UniversityIncyte CorporationTerminatedGraft Vs Host Disease | Steroid Refractory GVHDUnited States